The Online Investor

Slideshow Stock Splits

By The Online Investor Staff, updated Fri., May. 24, 8:02 AM

Slide #6. DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) 1 for 10 Reverse Split

Announced: 5/7/2019
Stock Split: 1 for 10
Record Date: 5/7/2019
Pay Date: 5/8/2019
DMPI Optionable?: No

DelMar Pharmaceuticals is a clinical stage company with a focus on the development of drugs for the treatment of cancer. Co.'s primary product candidate, VAL-083, is a small molecule chemotherapeutic, which means that the molecular structure of VAL-083 is not an analogue or derivative of any approved product, or in development for the treatment of cancer. VAL-083 is approved as a chemotherapy in China for the treatment of chronic myelogenous leukemia and lung cancer. Co. is developing VAL-083, a DNA-targeting agent, for the treatment of glioblastoma multiforme and potentially other solid tumors, including ovarian cancer.
DMPI Detailed Information Page & Split History »

Company Name: 
DelMar Pharmaceuticals, Inc

Open the DMPI Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Stock Splits Page |

Copyright © 1998 - 2019, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.